US equities |
NVDA $204.64 ▼-4.22% INTC $65.76 ▼-28.58% MU $884.74 ▼-5.30% AMZN $240.35 ▼-1.41% AAPL $344.63 ▼-1.23% SNDK $1,150.89 ▼-13.47% AMD $504.80 ▼-10.88% MSFT $521.91 ▼-1.55%
FinancialContent

Gain Therapeutics, Inc. - Common Stock (NQ:GANX)

1.130 -0.060 (-5.04%)
Delayed Quote Updated: 4:00 PM EDT, Oct 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gain Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
Gain Therapeutics to Attend the 2025 Maxim Growth Summit
From Gain Therapeutics, Inc.
Via GlobeNewswire
News headline image
Gain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinson’s Disease
Event to be held October 14th at 4 p.m. EST 
From Gain Therapeutics, Inc.
Via GlobeNewswire
News headline image
Gain Therapeutics Presents Initial Data from Phase 1b Clinical Study of GT-02287 in Parkinson’s Patients at International Congress of Parkinson’s Disease and Movement Disorders®
From Gain Therapeutics, Inc.
Via GlobeNewswire
News headline image
Gain Therapeutics to Participate at Drug Discovery Innovation Programme 2025
From Gain Therapeutics, Inc.
Via GlobeNewswire
News headline image
Gain Therapeutics Begins Its GT-02287 Phase 1b Extension Study in People with Parkinson’s Disease
From Gain Therapeutics, Inc.
Via GlobeNewswire
News headline image
Gain Therapeutics Receives Australian Approval of Phase 1b Dosing Extension and Reports Positive Independent Data Monitoring Committee Recommendation
From Gain Therapeutics, Inc.
Via GlobeNewswire
News headline image
Gain Therapeutics Reports Financial Results for Second Quarter 2025 and Provides Corporate Update
From Gain Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
 
Via Benzinga
News headline image
Gain Therapeutics to Present at BTIG Annual Virtual Biotechnology Conference
From Gain Therapeutics, Inc.
Via GlobeNewswire
News headline image
Gain Therapeutics Announces Pricing of $7.0 Million Public Offering
From Gain Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
US Futures Trade Mixed As June Inflation Ticks Up: ASML, Morgan Stanley, Goldman Sachs, BofA Earnings In Focus ↗
U.S. stock futures swung between gains and losses on Wednesday after ending on a mixed note on Tuesday. Futures of major benchmark indices were mixed. 
Via Benzinga
Topics Economy
News headline image
Why Data Storage Shares Are Trading Higher By 35%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
Tuesday's after hours session: top gainers and losers ↗
The regular session of the US market on Tuesday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements. 
Via Chartmill
News headline image
Gain Therapeutics Announces Proposed Public Offering
From Gain Therapeutics, Inc.
Via GlobeNewswire
News headline image
Gain Therapeutics Announces Completion of Target Enrollment in Phase 1b Clinical Study Evaluating GT-02287 in People With Parkinson’s Disease With or Without a GBA1 Mutation
From Gain Therapeutics, Inc.
Via GlobeNewswire
News headline image
Gain Therapeutics to Participate in Upcoming Investor Conferences
From Gain Therapeutics, Inc.
Via GlobeNewswire
News headline image
Gain Therapeutics Announces Oral Presentation at 2nd GBA1 Meeting
From Gain Therapeutics, Inc.
Via GlobeNewswire
News headline image
Gain Therapeutics Reports Financial Results for First Quarter 2025 and Provides Corporate Update
First Biomarker Analysis from Phase 1b Study of GT-02287 in Parkinson’s Disease Expected Mid-2025 
From Gain Therapeutics, Inc.
Via GlobeNewswire
News headline image
Gain Therapeutics Presents Preclinical Data at IAPRD 2025 30th World Congress on Parkinson’s Disease and Related Disorders
GT-02287 protects dopaminergic neurons against mitochondrial toxin MPP+ suggesting an action on mitochondrial GCase in addition to its improvement of lysosomal GCase activity 
From Gain Therapeutics, Inc.
Via GlobeNewswire
News headline image
Gain Therapeutics to Participate at The Citizens Life Sciences Conference
From Gain Therapeutics, Inc.
Via GlobeNewswire
News headline image
Gain Therapeutics Announces Oral Poster Presentation at IAPRD 2025 30th World Congress on Parkinson’s Disease and Related Disorders
From Gain Therapeutics, Inc.
Via GlobeNewswire
News headline image
Gain Therapeutics Presents Additional Preclinical Data and Design of Phase 1b Clinical Study of GT-02287 at AD/PD 2025 and Provides Enrollment Update
From Gain Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Gain Therapeutics Announces Poster Presentation at AD/PD 2025
From Gain Therapeutics, Inc.
Via GlobeNewswire
News headline image
Gain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2024 and Provides Corporate Update
First Analysis from Phase 1b Study of GT-02287 in Parkinson’s Disease Expected in Q2 2025 
From Gain Therapeutics, Inc.
Via GlobeNewswire
News headline image
Gain Therapeutics Doses First Participant in Phase 1b Clinical Trial of GT-02287 in Parkinson’s Disease
Via Get News
News headline image
Gain Therapeutics Doses First Participant in Phase 1b Clinical Trial of GT-02287 in Parkinson's Disease
Via ACCESS Newswire
News headline image
Gain Therapeutics Doses First Participant in Phase 1b Clinical Trial of GT-02287 in Parkinson’s Disease
Interim Analysis Expected End of 2Q 2025 
From Gain Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 Next >